What the Numbers Look Like The STEP 1 clinical trial, published in the New England Journal of Medicine in 2021, enrolled 1,961 adults with obesity and no diabetes
Our study was conducted in a single center
Here's why now is the right time: The future won't be defined by a single GLP-1 treatment, but by a continuum of optionsoral and injectable, first-line and maintenance, single- and dual-agonist - its getting complex out there, and it requires more than simply prescribing medications, but also active coordination and support
Discussion KOA is one of the most common disabling joint disorders, and approximately 44.7% of patients with OA are at risk of developing a disability in their lifetime [4]
Seminars in Thrombosis and Hemostasis , 2000, 26: 255-61
however, their use is increasing steadily in Chinese populations [28]